TheraRadar
← Back
Data updated: Sep 20, 2026

X GEN PHARMS

Generics
Pharmaceuticals

X GEN PHARMS is a generic drug manufacturer with 7 FDA-approved products.

1972
Since
7
Drugs
-
Trials
0
New Drugs (2yr)

Upcoming FDA Decisions

Full Calendar →
Nov 14, 2026 — IGALMI
Nov 30, 2026 — Povetacicept (ALPN-303)
Dec 3, 2026 — Zanzalintinib (XL-092) + atezolizumab
+2 more dates (Pro)

X GEN PHARMS's Key Drugs

X GEN PHARMS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

X GEN PHARMS's Recent FDA Approvals

New NDA/BLA approvals for X GEN PHARMS over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

X GEN PHARMS's Therapeutic Areas

Disease areas where X GEN PHARMS has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

X GEN PHARMS Pipeline Snapshot

Active clinical trials for X GEN PHARMS across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling